NexImmune (NEXI) has issued an update.
NexImmune, Inc. is undergoing a transition in its financial leadership, with Timothy Stover stepping down as the principal financial officer and principal accounting officer on April 16, 2024. He leaves without disputes over the company’s operations or practices. Albert N. Marchio II, with extensive experience in the pharmaceutical industry, will take over as the Interim Chief Financial Officer. Marchio’s appointment is part of a consulting agreement with Danforth Advisors, where he will receive indemnification and payment for his services. This change signifies a new chapter for NexImmune’s financial management.
For a thorough assessment of NEXI stock, go to TipRanks’ Stock Analysis page.
